deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT00904345

Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)

Phase II Study of RT Concurrent w/ Cetuximab in Patients w/ Locally Advanced Head & Neck SCC Who Do Not Qualify For Standard Chemotherapy Due To Age >70 Or Co-Morbidities

Sponsor: University of Michigan Rogel Cancer Center

Conditions Head and Neck Cancer
Interventions 50-60 Gy and 70 Gy Cetuximab
Updated 16 times since 2017 Last updated: Feb 3, 2021 Started: Apr 30, 2009 Primary completion: Dec 31, 2020 Completion: Dec 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Stopped early for funding and efficacy reasons.

Other terminated trials from University of Michigan Rogel Cancer Center

See all terminations from University of Michigan Rogel Cancer Center

Other Head and Neck Cancer trials with similar outcome

Browse all Head and Neck Cancer trials

A PHASE2 clinical study on Head and Neck Cancer, this trial is terminated or withdrawn. The trial is conducted by University of Michigan Rogel Cancer Center and has accumulated 16 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Dec 2018 · 4 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Dec 2019 · 9 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Dec 2022 · 21 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Mar 2021 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 11 earlier versions

  1. Feb 2021 — Mar 2021 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Dec 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Dec 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Aug 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  8. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

  9. Aug 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Feb 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Michigan Rogel Cancer Center
Data source: University of Michigan Rogel Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations